MAZE — Maze Therapeutics, Inc.
Is MAZE overbought or oversold? Here is the current MarketMoodz read.
Maze Therapeutics, Inc. (MAZE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $33.90. The rating moved from Neutral to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$33.90
- Last changeMoved from Neutral to Oversold on November 16, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Maze Therapeutics, Inc. is an early‑stage, genetics‑first biotech with potential for high upside if its discovery platform yields clinical proof of concept or attracts strategic partnerships. Financial visibility is limited in the provided data, raising uncertainty around cash runway and near‑term dilution risk. The current market backdrop is measured and not strongly favorable to small biotech rotation; however, ongoing large‑cap pharma acquisitiveness could create exit or collaboration pathways. Key drivers to monitor are clinical readouts, partnership announcements, and any clarified financial reporting. The balance of significant upside potential against binary clinical and financing risks leads to a neutral near‑term stance with heightened monitoring of company disclosures and trial milestones.
Key factors
- Genetics‑driven discovery platform with early‑stage pipeline that can produce high‑value, disease‑modifying targets if clinical proof of concept is achieved
- Pipeline is primarily preclinical/early clinical — upside is binary but large in the event of positive data or strategic partnerships
- No recent EDGAR filing comparison available in the provided dataset, creating visibility and financial‑health information gaps
- Macro market tone over the last four hours shows measured risk‑on with low volatility; environment is neutral-to-mildly supportive for selective biotech movers but flows favor large‑cap defensive pharma
- Large‑cap pharma M&A appetite and consolidation into specialty franchises could create strategic exit or partnership opportunities for attractive genetic targets
- Limited social/research sentiment available increases information asymmetry and short‑term trading unpredictability
Risks
- Binary clinical readouts: failed or delayed trials could produce sharp downside
- Unclear cash runway and financing needs; material dilution if capital raises are required
- Regulatory risk and long timelines from early development to commercialization
- Competition from larger, better‑funded pharmaceutical companies and other genetic/therapeutic platforms
- Low trading liquidity and potential for large intraday moves on news or thin order books
- Lack of recent public filings or visible financial updates increases model and valuation uncertainty
See today's live rating, score and targets
Members see the live hourly rating for MAZE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.